TP53 and urinary bladder cancer: Recently, an optimized CRISPR-Cas9 based light-inducible gene expression system in bladder cancer cell was developed [148] to control Tp53 gene expression in a dose-dependent manner and inhibit proliferation of cancer cell by modulating expression of p53 gene [148].